Unicycive Therapeutics Files 8-K with Financial Updates
Ticker: UNCY · Form: 8-K · Filed: Mar 30, 2026 · CIK: 0001766140
| Field | Detail |
|---|---|
| Company | Unicycive Therapeutics, Inc. (UNCY) |
| Form Type | 8-K |
| Filed Date | Mar 30, 2026 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, 8-k, reporting
Related Tickers: UNCY
TL;DR
UNCY filed an 8-K on 3/30/26 with financial results. Check it out.
AI Summary
Unicycive Therapeutics, Inc. filed an 8-K on March 30, 2026, reporting on its financial condition and results of operations. The filing includes a press release and financial statements, with the primary document being the 8-K filing itself.
Why It Matters
This filing provides investors with crucial updates on Unicycive Therapeutics' financial performance and operational status, enabling informed investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial reporting filing and does not indicate any immediate or significant risks.
Key Players & Entities
- Unicycive Therapeutics, Inc. (company) — Filer of the 8-K report
- 0001766140 (company) — CIK number for Unicycive Therapeutics, Inc.
- March 30, 2026 (date) — Filing date of the 8-K report
FAQ
What specific financial results are detailed in the 8-K filing?
The 8-K filing indicates that Item 2.02, Results of Operations and Financial Condition, is being reported, but the specific financial figures are not detailed in the provided filing summary.
What is the CIK number for Unicycive Therapeutics, Inc.?
The CIK number for Unicycive Therapeutics, Inc. is 0001766140.
When was this 8-K filing accepted by the SEC?
This 8-K filing was accepted by the SEC on March 30, 2026, at 07:29:20.
What are the business and mailing addresses for Unicycive Therapeutics, Inc.?
The business and mailing addresses for Unicycive Therapeutics, Inc. are both listed as 4300 EL CAMINO REAL, SUITE 210, LOS ALTOS CA 94022.
What types of documents are included in this 8-K filing?
This 8-K filing includes a current report, a press release dated March 30, 2026, and graphic files, along with XBRL data files.
Filing Stats: 503 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2026-03-30 07:29:20
Filing Documents
- ea0283942-8k_unicycive.htm (8-K) — 27KB
- ea028394201ex99-1.htm (EX-99.1) — 50KB
- ea028394201_ex99-1img1.jpg (GRAPHIC) — 5KB
- 0001213900-26-035961.txt ( ) — 254KB
- uncy-20260330.xsd (EX-101.SCH) — 3KB
- uncy-20260330_lab.xml (EX-101.LAB) — 33KB
- uncy-20260330_pre.xml (EX-101.PRE) — 22KB
- ea0283942-8k_unicycive_htm.xml (XML) — 3KB
02 Results of Operations and Financial Conditions
Item 2.02 Results of Operations and Financial Conditions. On March 30, 2026, Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the full year ended December 31, 2025 and provided a business update. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (d) Exhibits. 99.1 Press Release of Unicycive Therapeutics, Inc. dated March 30, 2026. 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 30, 2026 UNICYCIVE THERAPEUTICS, INC. By: /s/ Shalabh Gupta Shalabh Gupta Chief Executive Officer 2